By Rory Gallivan
LONDON--GlaxoSmithKline PLC (GSK.LN) Friday said the U.S. Food and Drug Administration has given its malaria treatment tafenoquine a designation that aims to speed up the approval process for drugs used to treat life-threatening diseases.
The FDA has granted tafenoquine Breakthrough Therapy designation, Glaxo said, adding that tafenoquine is not yet approved or licensed for use anywhere in the world.
-Shares at 1546 GMT, down a penny, or at 1,572 pence, valuing the company at GBP76.37 billion ($125.1 million).
Write to Rory Gallivan at firstname.lastname@example.org; Twitter: @RoryGallivan